Back to company

Novo Nordisk Research Center Gladsaxe ApS: Financial statements 2021

CVR: 39119374

Novo Nordisk Research Center Gladsaxe ApS (CVR 39119374) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 0 and a net result of DKK -6,196,311 compared with DKK 3,185,064 the year before. Equity amounted to DKK 2,940,920. The solvency ratio was 27.5%. The company had 3 employees in the financial year.

Gross Profit
0 kr.
Profit/Loss
-6,196,311 kr.
Equity
2,940,920 kr.
Total Assets
10,693,228 kr.
Employees
3

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021-0-6.2 mio.2.9 mio.3
2020-10.7 mio.3.2 mio.9.5 mio.5
2019-25.6 mio.14.4 mio.18.3 mio.5
2018-14.9 mio.9.8 mio.52 t.1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Novo Nordisk Research Center Gladsaxe ApS

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2021

Casper Tind Hansen joins the board of Novo Nordisk Research Center Gladsaxe ApSAug 9, 2021

As of August 9, 2021, Casper Tind Hansen has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.

Klaus Christian Schollmeier joins the board of Novo Nordisk Research Center Gladsaxe ApSAug 9, 2021

As of August 9, 2021, Klaus Christian Schollmeier has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.

Jakob Bondo Hansen joins Novo Nordisk Research Center Gladsaxe ApS as directorAug 9, 2021

As of August 9, 2021, Jakob Bondo Hansen is registered as director of Novo Nordisk Research Center Gladsaxe ApS.

Novo Nordisk Research Center Gladsaxe ApS: The 2020 annual report is outJun 14, 2021

Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2020. Gross profit came to DKK 10,676,598, and the net result was DKK 3,185,064.

About Novo Nordisk Research Center Gladsaxe ApS

Novo Nordisk Research Center Gladsaxe ApS is a Danish company of the type Anpartsselskab based in Bagsværd, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Embark Biotech ApS and Embark Biotech IvS. The management consists of Rikke Ryttergaard Andersen. The company is owned by NOVO NORDISK A/S. The company has 7 employees. In 2025, the company reported a gross profit of DKK -1,000 and a net result of DKK 48,000 compared with DKK 6,174,000 the year before. Equity amounted to DKK 807,000.

Other financial years